Comparative analysis of micro-RNAs in human papillomavirus-positive versus -negative oropharyngeal cancers.
Oncogenic mechanisms of human papillomavirus (HPV)-positive oropharyngeal cancer are still poorly characterized. Analysis of their microRNA expression profile might provide valuable information.



The microRNA expression profiles were analyzed by micro-arrays in 26 oropharyngeal cancers. A microRNA signature specific to HPV-status was identified by analyzing a learning/training set consisting of 16 oropharyngeal cancers. The robustness of this signature was further confirmed by blind case-by-case classification of a validation set composed of 10 independent tumors. Putative targeted molecular pathways were proposed using DIANA miRPath online software (http://microrna.gr/mirpath).



We have identified 25 miRNA signatures, which discriminates HPV16-positive oropharyngeal cancer from their HPV-negative counterparts. These 25 microRNAs play a potential role in Wnt and PI3K-pathways, cell-adhesion/cell-polarity, and the cytoskeleton regulation.



Our study contributes to a better understanding of pathogenic mechanisms involved in the development of HPV-positive oropharyngeal cancer and in the identification of potential therapeutic molecular targets. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.
ER2 Unit and GRC10, Université Pierre et Marie Curie, Paris, France. haitham.mirghani@gustaveroussy.fr.|Department of Head and Neck Surgery, Institut de Cancérologie Gustave Roussy, Villejuif, France. haitham.mirghani@gustaveroussy.fr.
Haitham
H
Mirghani
CEA, DSV, iRCM, Laboratory of Experimental Cancerology, Fontenay-aux-Roses, Cedex, France.
Nicolas
N
Ugolin
CEA, DSV, iRCM, Laboratory of Experimental Cancerology, Fontenay-aux-Roses, Cedex, France.
Catherine
C
Ory
CEA, DSV, iRCM, Laboratory of Experimental Cancerology, Fontenay-aux-Roses, Cedex, France.
Maud
M
Goislard
Department of Pathology, GHUEP, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France.
Marine
M
Lefèvre
PartnerChip, Evry, France.
Sylvain
S
Baulande
Laboratory of Clinical and Experimental Pathology and Biobank of CHUN, Pasteur Hospital, Nice, France.
Paul
P
Hofman
ER2 Unit and GRC10, Université Pierre et Marie Curie, Paris, France.|Department of Otolaryngology - Head and Neck Surgery, GHUEP, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.
Jean Lacau St
JL
Guily
CEA, DSV, iRCM, Laboratory of Experimental Cancerology, Fontenay-aux-Roses, Cedex, France.
Sylvie
S
Chevillard
ER2 Unit and GRC10, Université Pierre et Marie Curie, Paris, France.|Tumours Genomic Unit, GHUEP, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.
Roger
R
Lacave
D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000821:virology; D005260:Female; D052162:Human papillomavirus 16 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000235:genetics* / Q000821:virology; D030361:Papillomavirus Infections / Q000150:complications; D017423:Sequence Analysis, RNA; D059467:Transcriptome
D035683:MicroRNAs
PI3K pathway; Wnt pathway; gene expression profile; human papillomavirus 16; micro/miRNA; microarray; oropharyngeal/oropharynx cancer